Transenterix Inc (NYSEMKT:TRXC) , which happens to be one of the top medical device companies that has lately been pioneering the use of robotics in a move to try and enhance minimally invasive surgery has today made the much awaited for news.
It has as a matter of fact cleared the air surrounding the matter about rumors that it was indeed considering entering a debt financing agreement. It hopes that within a short time frame it will be able to generate about $17.0 million in terms of loans and that is of course if everything works out perfectly well with Innovatus Capital Partners, LLC (“Innovatus”).
The President and Chief Executive Officer of TransEnterix, Todd M. Pope while addressing a number of top news reporters outlined, “We are pleased to partner with Innovatus for our debt financing needs. In conjunction with our recently completed equity transaction, this capital will allow us to continue our commercialization efforts in Europe focus on the Senhance 510(k) clearance process and expand our U.S. market development efforts.”
One thing that is beyond any reasonable cloud of doubt is that Innovatus has made tremendous steps in terms of going higher the ladder to become a flexible and committed capital company and this is of course happening during a very critical stage of growth.
May 10, 2017 witnessed the provider make entry into a loan and security agreement with Innovatus. Sources indicate that Innovatus has shown great willingness to move ahead and of course make specific term loans in the total principal amount which is about $17.0 million in terms of value.
One thing that is for sure is the fact that Innovatus is indeed very much excited about the joining in of TransEnterix in the promising future that will have robotics come in play in a major way especially in the medical field.
Let’s face it; offering capital to such a top end as well as innovative provider comes about as a strategic priority for Innovatus and according to company insiders, there is great hope that indeed the relationship will be upheld for a long time to come.
